GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:07 2024-09-13 EDT			5-day change	1st Jan Change
1,633.50 ^GBX	-0.31%		-1.09%	+12.64%

01:10pm	GSK Says Blenrep Granted Breakthrough Therapy Designation in China	MT
12:23pm	GSK: innovative therapy designation granted in China	CF

GSK celebrates US FDA backing for expanded use of cancer drug Jemperli

August 02, 2024 at 01:56 am

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration expanded the use of its cancer medicine Jemperli, also known as dostarlimab, when combined with chemotherapy.

The London-based pharmaceutical company said the "approval now includes mismatch repair proficient/microsatellite stable tumours, which represent majority of endometrial cancer cases".

GSK said the approval is for all adults with primary advanced or recurrent endometrial cancer, a cancer that affects the uterus.

GSK said it was the first and only immuno-oncology-based treatment to show an overall survival benefit, citing phase 3 trial data. At the 2.5-year landmark, 61% of patients in the Jemperli plus chemotherapy group compared to 49% in the chemotherapy group were alive.

GSK shares closed 0.5% higher at 1,519.00 pence each on Thursday in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Latest news about GSK plc

GSK Says Blenrep Granted Breakthrough Therapy Designation in China	07:10am	MT
GSK: innovative therapy designation granted in China	06:23am	CF
GSK : Goldman Sachs reaffirms its Neutral rating	06:00am	ZD
GSK myeloma treatment given breakthrough therapy designation in China	04:16am	AN
GSK's Plasma Cell Cancer Treatment Receives Breakthrough Designation in China	02:42am	MT
European Equities Close Higher in Thursday Trading; European Central Bank Cuts Rates by 25 Basis Points	09-12	MT
ECB to cut rates without lowering its guard	09-12
GSK Reports Positive Resuts in Trial of mRNA Influenza Vaccine	09-12	MT
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme	09-12	CI
GSK: positive results for influenza vaccine	09-12	CF
GSK welcomes positive findings on possible flu treatment	09-12	AN
British drugmaker GSK moves mRNA flu vaccine to late-stage trials	09-12	RE
GSK's mRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results	09-12	DJ
Trainline lifts guidance; Kier Group earnings climb	09-12	AN
GSK Says mRNA Flu Shot Triggers Overall Antibody Titers in Mid-stage Study	09-12	MT
GSK Resolves Latest Zantac Case in US Through Confidential Settlement	09-12	MT
GSK Reaches Another Settlement in Zantac Litigation	09-11	DJ
GSK plc Announces Change of Registered Office Address	09-11	CI
FTSE 100 in uninspiring gain before US data	09-11	AN
GSK's HPV Vaccine Misses Main Goal in Early-to-Mid Stage Study	09-11	MT
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial	09-11	CI
GSK: shares fall back after disappointing clinical study	09-11	CF
GSK stresses need for innovation as herpes vaccine fails to progress	09-11	AN
GSK : Gets a Neutral rating from Goldman Sachs	09-11	ZD
GSK's Herpes Vaccine Candidate Fails to Meet Efficacy Goal in Early-stage Trial	09-11	MT

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

70,212

Sector

Pharmaceuticals

Calendar

2024-09-18 - Bank of America Global Healthcare Conference

More about the company